Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.

Authors:
Sabbah HN.

Journal:
Heart Fail Rev

Publication Year: 2021

DOI:
10.1007/s10741-021-10177-8

PMCID:
PMC9388406

PMID:
34623544

Journal Information

Full Title: Heart Fail Rev

Abbreviation: Heart Fail Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestDr. Sabbah is a consultant to Stealth Biotherapeutics, Inc. and member of their Scientific Advisory Board. Dr. Sabbah also serves as a consultant to Bayer AG and Arena Pharmaceuticals, Inc. and has received research grant funding from Bayer AG, Arena Pharmaceuticals, Novartis Corp., and Bristol-Myers Squibb Company. Conflict of interest Dr. Sabbah is a consultant to Stealth Biotherapeutics, Inc. and member of their Scientific Advisory Board. Dr. Sabbah also serves as a consultant to Bayer AG and Arena Pharmaceuticals, Inc. and has received research grant funding from Bayer AG, Arena Pharmaceuticals, Novartis Corp., and Bristol-Myers Squibb Company."

Evidence found in paper:

"Funding This work is supported in part by Stealth BioTherapeutics, Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025